05:18 AM EDT, 03/13/2024 (MT Newswires) -- Pfizer ( PFE ) said Wednesday that the European Commission has granted marketing authorization for its Prevenar 20 vaccine as active immunization against "the 20 serotypes responsible for the majority of currently circulating pneumococcal disease in the European Union" for infants, children and adolescents of six weeks old to 18 years old.

The company said the approval was based on the results of a phase 3 trial that expanded the vaccine's safety, tolerability, and immunogenicity data. The marketing authorization covers all 27 EU member states, as well as Iceland, Lichtenstein and Norway, Pfizer ( PFE ) added.

Prevenar 20 is also approved in the US and several other countries such as Canada, Australia, and Brazil, said Pfizer ( PFE ).